Human toxoplasmosis–Searching for novel chemotherapeutics

Biomedicine and Pharmacotherapy

Volumn 82, Issue , 2016, Pages 677-684

  Antczak, Magdalena ^a   Dzitko, Katarzyna ^a   Długońska, Henryka ^a  

^a UNIVERSITY OF LODZ   (Poland)

Author keywords

Chemotherapy; New anti toxoplasmic compounds; T. gondii; Toxoplasmosis

Indexed keywords

COCCIDIOSTATIC AGENT; ENZYME INHIBITOR; HERBACEOUS AGENT; NATURAL PRODUCT; NEW DRUG; ANTIPROTOZOAL AGENT;

ANTIPROTOZOAL ACTIVITY; CHEMOTHERAPY; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG REPOSITIONING; DRUG SELECTIVITY; DRUG SYNTHESIS; HERBAL MEDICINE; HUMAN; IC50; MEDICINAL PLANT; NONHUMAN; PRIORITY JOURNAL; REVIEW; TOXOPLASMA GONDII; TOXOPLASMOSIS; ANIMAL; PARASITOLOGY; PRECLINICAL STUDY; TOXOPLASMA;

ANIMALS; ANTIPROTOZOAL AGENTS; DRUG EVALUATION, PRECLINICAL; HUMANS; TOXOPLASMA; TOXOPLASMOSIS;

EID: 84979626625     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.05.041     Document Type: Review

References (88)

1. [1] Hill, D.E., Chirukandot, S., Dubey, J.P., Biology and epidemiology of Toxoplasma gondii in man and humans. Anim. Health Res. Rev. 6 (2005), 41–61.
2. [2] Montoya, J.G., Liesenfeld, O., Toxoplasmosis. Lancet 363 (2004), 1965–1976.
3. [3] Petersen, E., Toxoplasmosis. Semin. Fetal. Neonatal Med. 12 (2007), 214–223.
4. [4] Paquet, C., Yudin, M.H., Society of Obstetricians and Gynaecologists of Canada,Toxoplasmosis in pregnancy: prevention, screening, and treatment. J. Obstet. Gynaecol. Can. 35 (2013), 78–81.
5. [5] Oz, H.S., Maternal and congenital toxoplasmosis, currently available and novel therapies in horizon. Front. Microbiol. 5 (2014), 1–6.
6. [6] Flegr, J., Prandota, J., Sovičková, M., Israili, Z.H., Toxoplasmosis—a global threat, Correlation of latent toxoplasmosis with specific disease burden in a set of 88 countries. PLoS One, 9, 2014, e90203.
7. [7] Andrews, K.T., Fisher, G., Skinner-Adams, T.S., Drug repurposing and human parasitic protozoan diseases. Int. J. Parasitol. Drugs Drug Resist. 4 (2014), 95–111.
8. [8] Kaplan, J.E., Benson, C., Holmes, K.K., Brooks, J.T., Pau, A., Masur, H., Centers for Disease Control Prevention (CDC), National Institutes of Health, HIV Medicine Association of the Infectious Diseases Society of America, Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm. Rep. 58:4 (2009), 1–207.
9. [9] Greif, G., Harder, A., Haberkorn, A., Chemotherapeutic approaches to protozoa: coccidiae—current level of knowledge and outlook. Parasitol. Res. 87 (2001), 973–975.
10. [10] Bodaghi, B., Touitou, V., Fardeau, C., Paris, L., Le Hoang, P., Toxoplasmosis: new challenges for an old disease. Eye (Lond) 26 (2012), 241–244.
11. [11] McCabe, R.E., Antitoxoplasma chemotherapy. Joynson, D.M.H., Wreghitt, T.G., (eds.) Toxoplasmosis. A Compressive Clinical Guide, 2001, Cambridge University Press, 319–359.
12. [12] Maenz, M., Schlüter, D., Liesenfeld, O., Schares, G., Gross, U., Pleyer, U., Ocular toxoplasmosis past, present and new aspects of an old disease. Prog. Retin. Eye Res. 39 (2014), 77–106.
13. [13] Rajapakse, S., Chrishan Shivanthan, M., Samaranayake, N., Rodrigo, C., Deepika Fernando, S., Antibiotics for human toxoplasmosis: a systematic review of randomized trials. Pathog. Glob. Health. 107 (2013), 162–169.
14. [14] Donald, R.G.K., Toxoplasma as a model system for apicomplexan drug discovery. Weiss, L.M., Kami, K., (eds.) Toxoplasma gondii. The Model Apicomplexan—Perspectives and Methods, 2007, Acad. Press, London, 505–538.
15. [15] Fichera, M.E., Ross, D.S., A plastid organelle as a drug target in apicomplexan parasites. Nature 390 (1997), 407–409.
16. [16] Paquet, C., Yudin, M.H., Toxoplasmosis in pregnancy: prevention, screening, and ttreatment. J. Obster. Gynaecol. Can. 35 (2013), 78–81.
17. [17] Montoya, J.G., Remington, J.S., Management of Toxoplasma gondii infection during pregnancy. Clin. Infect. Dis. 47 (2008), 554–566.
18. [18] Doliwa, C., Escotte-Binet, S., Aubert, D., Velard, F., Schmid, A., Geers, R., Villena, I., Induction of sulfadiazine resistance in vitro in Toxoplasma gondii. Exp. Parasitol. 133 (2013), 131–136.
19. [19] Sims, P.F.G., Drug resistance in Toxoplasma gondii. Douglas, L., Mayers, M.D., (eds.) Antimicrobial Drug Resistance, Clinical and Epidemiological Aspects, Series Infectious Disease, 2009, Humana Press, 1121–1126.
20. [20] Müller, J., Hemphill, A., Drug target identification in intracellular and extracellular protozoan parasite. Curr. Top. Med. Chem. 11 (2011), 2019–2038.
21. [21] Müller, J., Hemphill, A., New approaches for the identification of drug targets in protozoan parasite. Int. Rev. Cell. Mol. Biol. 301 (2013), 359–401.
22. [22] Jin, C.M., Kaewintajuk, K., Jiang, J.H., Jeong, W., Kamata, M., Kim, H.S., Wataya, Y., Park, H., Toxoplasma gondii: a simple high-throughput assay for drug screening in vitro. Exp. Parasitol. 121 (2009), 132–136.
23. [23] Pelphrey, P.M., Popov, V.M., Joska, T.M., Beierlein, J.M., Bolstad, E.S., Fillingham, Y.A., Wright, D.L., Anderson, A.C., Highly efficient ligands for dihydrofolate reductase from Cryptosporidium hominis and Toxoplasma gondii inspired by structural analysis. J. Med. Chem. 50 (2007), 940–950.
24. [24] Rosowsky, A., Papoulis, A.T., Queener, S.F., 2,4-Diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidine analogues of trimethoprim as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase. J. Med. Chem. 41 (1998), 913–918.
25. [25] Gangjee, A., Zhu, Y., Queener, S.F., 6-Substituted 2,4-diaminopyrido[3,2-d]pyrimidine analogues of piritrexim as inhibitors of dihydrofolate reductase from rat liver, Pneumocystis carinii, and Toxoplasma gondii and as antitumor agents. J. Med. Chem. 23 (1998), 4533–4541.
26. [26] Ojo, K.K., Larson, E.T., Keyloun, K.R., Castaneda, L.J., DeRocher, A.E., Inampudi, K.K., Kim, J.E., Arakaki, T.L., Murphy, R.C., Zhang, L., Napuli, A.J., Maly, D.J., Verlinde, C.L.M.J., Buckner, F.S., Parsons, M., Hol, W.G.J., Merritt, E.A., Van Voorhis, W.C., Toxoplasma gondii calcium-dependent protein kinase 1 inhibitor. Nat. Struct. Mol. Biol. 17 (2010), 602–607.
27. [27] Lourido, S., Zhang, C., Lopez, M.S., Tang, K., Barks, J., Wang, Q., Wildman, S.A., Shokat, K.M., Sibley, L.D., Optimizing small molecule inhibitors of calcium-dependent protein kinase 1 to prevent infection by Toxoplasma gondii. J. Med. Chem. 56 (2013), 3068–3077.
28. [28] Johnson, S.M., Murphy, R.C., Geiger, J.A., DeRocher, A.E., Zhang, Z., Ojo, K.K., Larson, E.T., Perera, B.G., Dale, E.J., He, P., Reid, M.C., Fox, A.M., Mueller, N.R., Merritt, E.A., Fan, E., Parsons, M., Van Voorhis, W.C., Maly, D.J., Development of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) inhibitors with potent anti-toxoplasma activity. J. Med. Chem. 55 (2012), 2416–2426.
29. [29] Hui, R., El Bakkuri, M., Sibley, L.D., Designing selective inhibitors for calcium-dependent protein kinases in apicomplexans. Trends Pharmacol. Sci. 36 (2015), 452–460.
30. [30] Wu, P., Nielsen, T.E., Clause, M.H., FDA-approved small molecule kinase inhibitors. Trends Pharmacol. Sci. 36 (2015), 422–439.
31. [31] Winzer, P., Müller, J., Aguado-Martinez, A., Rahman, M., Balmer, V., Manse, V., Ortega-Mora, L.M., Ojo, K.K., Fan, E., Maly, D.J., Van Voorhis, W.C., Hemphill, A., In vitro and in vivo effects of the bumped kinase inhibitor 1294 in the related cyst-forming apicomplexans Toxoplasma gondii and Neospora caninum. Antimicrob. Agents Chemother. 59 (2015), 6361–6374.
32. [32] Kim, Y.A., Sharon, A., Chu, C.K., Rais, R.H., Al Safarjalani, O.N., Naguib, F.N.M., et al. Structure–activity relationships of 7-deaza-6-benzylthioinosine analogues as ligands of Toxoplasma gondii adenosine kinase. J. Med. Chem. 51 (2008), 3934–3945.
33. [33] Al Safarjalani, O.N., Rais, R.H., Kim, Y.A., Chu, C.K., Naguib, F.N.M., el Kouni, M.H., 7-Deaza-6-benzylthioinosine analogues as subversive substrate of Toxoplasma gondii adenosine kinase: activities and selective toxicities. Biochem. Pharmacol. 76 (2008), 958–966.
34. [34] Tipparaju, S.K., Muench, S.P., Mui, E.J., Ruzheinikov, S.N., Lu, J.Z., Hutson, S.L., Kirisits, M.J., Prigge, S.T., Roberts, C.W., Henriquez, F.L., Kozikowski, A.P., Rice, D.W., McLeod, R.L., Identification and development of novel inhibitors of Toxoplasma gondii enoyl reductase. J. Med. Chem. 53 (2010), 6287–6300.
35. [35] Zeng, Y.B., Dong, H., Han, H.Y., Jiang, L.L., Zhao, Q.P., Zhu, S.H., Ma, W.J., Cheng, J., Huang, B., The ultrastructural effects of sulfachloropyrazine on Toxoplasma gondii tachyzoites. Iran. J. Parasitol. 8 (2013), 73–77.
36. [36] Zaware, N., Sharma, H., Yang, J., Devambatla, R.K.V., Queener, S.F., Anderson, K.S., Gangjee, A., Discovery of potent and selective inhibitors of Toxoplasma gondii thymidylate synthase for opportunistic infections. ACS. Med. Chem. Lett. 4 (2013), 1148–1151.
37. [37] Yang, Z., Ahn, H.J., Nam, H.W., Gefitinib inhibits the growth of Toxoplasma gondii in HeLa cells. Korean J. Parasitol. 52 (2014), 439–441.
38. [38] Recher, M., Barboza, A.P., Li, Z.H., Galizzi, M., Ferrer-Casal, M., Szajnman, S.H., Docampo, R., Moreno, S.N., Rodriguez, J.B., Design synthesis and biological evaluation of sulfur-containing 1,1-bisphosphonic acids as antiparasitic agents. Eur. J. Med. Chem. 60 (2013), 431–440.
39. [39] Camara, D., Bisanz, C., Barette, C., Van Daele, J., Human, E., Barnard, B., Van der Straeten, D., Stove, C.P., Inhibition of p-aminobenzoate and folate syntheses in plants and apicomplexan parasites by natural product rubresceine. J. Biol. Chem. 287 (2012), 22367–22376.
40. [40] Dzitko, K., Paneth, A., Plech, T., Pawełczyk, J., Węglińska, L., Paneth, P., Triazole-based compound as a candidate to develop novel medicines to treat toxoplasmosis. Antimicrob. Agents Chemother. 58 (2014), 7583–7585.
41. [41] Sonda, S., Sala, G., Ghidoni, R., Hemphill, A., Pieters, J., Inhibitory effect of aureobasidin A on Toxoplasma gondii. Antimicrob. Agents Chemother. 49 (2005), 1794–1801.
42. [42] Martins-Duarte, E.S., Jones, S.M., Gilbert, I.H., Atella, G.C., de Souza, W., Vommaro, R.C., Thiolactomycin analogues as potential anti-Toxoplasma gondii agents. Parasitol. Int. 58 (2009), 411–415.
43. [43] Gupta, N., Zahn, M.M., Coppens, I., Joiner, K.A., Voelker, D.R., Selective disruption of phosphatidylcholine metabolism of the intracellular parasite Toxoplasma gondii arrests its growth. J. Biol. Chem. 280 (2005), 16345–16353.
44. [44] Doggett, J.S., Nilsen, A., Forquer, I., Wegmann, K.W., Jones-Brando, L., Yolken, R.H., Bordón, C., Charman, S.A., Katneni, K., Schultz, T., Burrows, J.N., Hinrichs, D.J., Meunier, B., Carruthers, V.B., Riscoe, M.K., Endochin-like quinolones are highly efficacious against acute and latent experimental toxoplasmosis. Proc. Natl. Acad. Sci. U S A. 109 (2012), 15936–15941.
45. [45] Konrad, C., Queener, S.F., Wek, R.C., Sullivan, W.J. Jr., Inhibitors of eIF2α dephosphorylation slow replication and stabilize latency in Toxoplasma gondii. Antimicrob. Agents Chemother. 57 (2013), 1815–1822.
46. [46] Nagano, S., Lin, T.Y., Edula, J.R., Heddle, J.G., Unique feature of apicoplast DNA gyrases from Toxoplasma gondii and Plasmodium falciparum. BMC Bioinf., 15, 2014, 416.
47. [47] Wei, S., Daniel, B.J., Brumlik, M.J., Burow, M.E., Zou, W., Khan, I.A., Wadsworth, S., Siekierka, J., Curiel, T.J., Drugs designed to inhibit human p38 mitogen-activated protein kinase activation treat Toxoplasma gondii and Encephalitozoon cuniculi infection. Antimicrob. Agents Chemother. 51 (2007), 4324–4328.
48. [48] Dantas-Leite, L., Urbina, J.A., de Souza, W., Vommaro, R.C., Selective anti-Toxoplasma gondii activities of azasterols. Int. J. Antimicrob. Agents. 23 (2004), 620–626.
49. [49] Martins-Duarte, E.S., Urbina, J.A., de Souza, W., Vommaro, R.C., Antiproliferative activities of two novel quinuclidine inhibitors against Toxoplasma gondii tachyzoites in vitro. J. Antimicrob. Chemother. 58 (2006), 59–65.
50. [50] Kamau, E.T., Srinivasan, A.R., Brown, M.J., Fair, M.G., Caraher, E.J., Boyle, J.P., A focused small-molecule screen identifies 14 compounds with distinct effects on Toxoplasma gondii. Antimicrob. Agents Chemother. 56 (2012), 5581–5590.
51. [51] Choi, H.J., Yu, S.T., Lee, K.I., Choi, J.K., Chang, B.Y., Kim, S.Y., Ko, M.H., Song, H.O., Park, H., 6-trifluoromethyl-2-thiouracil possesses anti-Toxoplasma gondii effect in vitro and in vivo with low hepatotoxicity. Exp. Parasitol. 143 (2014), 24–29.
52. [52] Kadri, D., Crater, A.K., Lee, H., Solomon, V.R., Ananvoranich, S., The potential of quinoline derivatives for the treatment of Toxoplasma gondii infection. Exp. Parasitol. 145 (2014), 135–144.
53. [53] Hencken, C.P., Jones-Brando, L., Bordón, C., Stohler, R., Mott, B.T., Yolken, R., Posner, G.H., Woodard, L.E., Thiazole oxadiazole, and carboxamide derivatives of artemisinin are highly selective and potent inhibitors of Toxoplasma gondii. J. Med. Chem. 53 (2010), 3594–3601.
54. [54] Leepin, A., Stüdli, A., Brun, R., Stephens, C.E., Boykin, D.W., Hemphill, A., Host cells participate in the in vitro effects of novel diamidine analogues against tachyzoites of the intracellular apicomplexan parasites Neospora caninum and Toxoplasma gondii. Antimicrob. Agents Chemother. 52 (2008), 1999–2008.
55. [55] Barna, F., Debache, K., Vock, C.A., Küster, T., Hemphill, A., In vitro effects of novel ruthenium complexes in Neospora caninum and Toxoplasma gondii tachyzoites. Antimicrob. Agents Chemother. 57 (2013), 5747–5774.
56. [56] Liesen, A.P., de Aquino, T.M., Carvalho, C.S., Lima, V.T., de Araújo, J.M., de Lima, J.G., de Faria, A.R., de Melo, E.J., Alves, A.J., Alves, E.W., Alves, A.Q., Góes, A.J., Synthesis and evaluation of anti-Toxoplasma gondii and antimicrobial activities of thiosemicarbazides 4-thiazolidinones and 1,3,4-thiadiazoles. Eur. J. Med. Chem. 45 (2010), 3685–3691.
57. [57] Dzitko, K., Paneth, A., Plech, T., Pawełczyk, J., Stączek, P., Stefańska, J., Paneth, P., 1,4-Disubstituted thiosemicarbazide derivatives are potent inhibitors of Toxoplasma gondii proliferation. Molecules 19 (2014), 9926–9943.
58. [58] Müller, J., Limban, C., Stadelmann, B., Missir, A.V., Chirita, I.C., Chifiriuc, M.C., Nitulescu, G.M., Hemphill, A., Thioureides of 2-(phenoxymethyl)benzoic acid 4-R substituted: a novel class of anti-parasitic compounds. Parasitol. Int. 58 (2009), 128–135.
59. [59] Portes Jde, A., Netto, C.D., da Silva, A.J., Costa, P.R., DaMatta, R.A., dos Santos, T.A., De Souza, W., Seabra, S.H., A new type of pterocarpanquinone that affects Toxoplasma gondii tachyzoites in vitro. Vet. Parasitol. 186 (2012), 261–269.
60. [60] Ferreira, R.A., de Oliveira, A.B., Gualberto, S.A., Miguel Del Corral, J.M., Fujiwara, R.T., Gazzinelli Guimarães, P.H., de Almeida Vitor, R.W., New naphthoquinones and an alkaloid with in vitro activity against Toxoplasma gondii RH and EGS strains. Exp. Parasitol. 132 (2012), 450–457.
61. [61] Alomar, M.L., Rasse-Suriani, F.A.O., Ganuza, A., Cóceres, V.M., Cabrerizo, F.M., Angel, S.O., In vitro evaluation of β-carboline alkaloids as potential anti-Toxoplasma agents. BMC. Res. Notes., 6, 2013, 193.
62. [62] Ishiwa, A., Kobayashi, K., Takemae, H., Sugi, T., Gong, H., Recuenco, F.C., Murakoshi, F., Inomata, A., Horimoto, T., Kato, K., Effects of dextran sulfates on the acute infection and growth stages of Toxoplasma gondii. Parasitol. Res. 112 (2013), 4169–4176.
63. [63] Shubar, H.M., Mayer, J.P., Hopfenmüller, W., Liesenfeld, O., A new combined flow-cytometry-based assay reveals excellent activity against Toxoplasma gondii and low toxicity of new bisphosphonates in vitro and in vivo. J. Antimicrob. Chemother. 61 (2008), 611110–611119.
64. [64] Baramee, A., Coppin, A., Mortuaire, M., Pelinski, L., Tomavo, S., Brocard, J., Synthesis and in vitro activities of ferrocenic aminohydroxynaphthoquinones against Toxoplasma gondii and Plasmodium falciparum. Bioorg. Med. Chem. 14 (2006), 1294–1302.
65. [65] Bilgin, M., Yıldırım, T., Hökelek, M., In vitro effects of Ivermectin and Sulphadiazine on Toxoplasma gondii. Balkan. Med. J. 30 (2013), 19–22.
66. [66] Andrews, K.T., Fisher, G., Skinner-Adams, T.S., Drug repurposing and protozoan diseases. Int. J. Parasitol. Drugs Resist. 4 (2014), 95–111.
67. [67] Andrade, R.M., Chaparro, J.D., Capparelli, E., Reed, S.L., Auranofin against Toxoplasma gondii in vitro and in an in vivo experimental model of acute toxoplasmosis. PLoS Negl. Trop. Dis., 8, 2014, e2973.
68. [68] Boyom, F.F., Fokou, P.V., Tchokouaha, L.R., Spangenberg, T., Mfopa, A.N., Kouipou, R.M., Mbouna, C.J., Donfack, V.F., Zollo, P.H., Repurposing the open access malaria box to discover potent inhibitors of Toxoplasma gondii and Entamoeba histolytica. Antimicrob. Agents Chemother. 58 (2014), 5848–5854.
69. [69] Montazeri, M., Daryani, A., Ebrahimzadeh, M., Ahmadpour, E., Sharif, M., Sarvi, S., Effect of propranolol alone and in combination with pyrimethamine on acute murine toxoplasmosis. Jundishapur. J. Microbiol., 8, 2015, e22572.
70. [70] Eissa, M.M., Barakat, A.M.A., Amer, E.I., Younis, L.K., Could miltefosine be used as a therapy for toxoplasmosis. Exp. Parasitol. 157 (2015), 12–22.
71. [71] Barna, F., Debache, K., Vock, C.A., Küster, T., Hemphill, A., In vitro effects of novel ruthenium complexes in Neospora caninum and Toxoplasma gondii tachyzoites. Antimicrob. Agents Chemother. 57 (2013), 5747–5754.
72. [72] Gueye, P.E.O., Diallo, M., Deme, A.B., Badiane, A.S., Dior, D.M., Ahouidi, A., Abdoul, A.N., Dieng, T., Lutgen, P., Mboup, S., Sarr, O., Tea Artemisia annua inhibits Plasmodium falciparum isolates collected in Pikine, Senegal. African J. Biochem. Res. 7 (2013), 107–112.
73. [73] de Oliveira, T.C., Silva, D.A., Rostkowska, C., Béla, S.R., Ferro, E.A., Magalhães, P.M., Mineo, J.R., Toxoplasma gondii: effects of Artemisia annua L. on susceptibility to infection in experimental models in vitro and in vivo. Exp. Parasitol. 122 (2009), 233–241.
74. [74] Schultz, T.L., Hencken, C.P., Woodard, L.E., Posner, G.H., Yolken, R.H., Jone-Branmdo, L., Carruther, V.B., A thiazole derivative of artemisinin moderately reduces Toxoplasma gondii burden in infected mice. J. Parasitol. 100 (2014), 516–521.
75. [75] Choi, K.M., Gang, J., Yun, J., Anti-Toxoplasma gondii RH strain activity of herbal extracts used in traditional medicine. Int. J. Antimicrob. Agents. 32 (2008), 360–362.
76. [76] Kavitha, N., Noordin, R., Chan, K.L., Sasidharan, S., In vitro anti-Toxoplasma gondii activity of root extract/fractions of Eurycoma longifolia Jack. BMC. Complement Altern. Med., 12, 2012, 91.
77. [77] Hong, S., Lee, H.-A., Lee, Y-s1., Chung, Y.-H., Kim, O., Anti-toxoplasmosis effect of Dictamnus dasycarpus extract against Toxoplasma gondii. J. Biomed. Res. 15 (2014), 007–011.
78. [78] Jiang, J.H., Jin, C.M., Kim, Y.C., Kim, H.S., Park, W.C., Park, H., Anti-toxoplasmosis effects of oleuropein isolated from Fraxinus rhychophylla. Biol. Pharm. Bull. 31 (2008), 2273–2276.
79. [79] Pillai, S., Mahmud, R., Lee, W.C., Perumal, S., Anti-parasitic activity of Myristica fragrans Houtt. Essential oil against Toxoplasma gondii parasite. APCBEE Procedia. 2 (2012), 92–96.
80. [80] Dinan, L., The Karlson lecture. Phytoecdysteroids: what use are they. Arch. Insect. Biochem. Physiol 72 (2009), 126–141.
81. [81] Subeki, Matsuura, H., Takahashi, K., Yamasaki, M., Yamato, O., Maede, Y., Katakura, K., Suzuki, M., Trimurningsih, Chairul, Yoshihara, T., Antibabesial activity of protoberberine alkaloids and 20-hydroxyecdysone from Arcangelisia flava against Babesia gibsoni in culture. J. Vet. Med. Sci. 67 (2005), 223–227.
82. [82] Dzitko, K., Grzybowski, M.M., Pawełczyk, J., Dziadek, B., Gatkowska, J., Stączek, P., Długońska, H., Phytoecdysteroids as modulators of the Toxoplasma gondii growth rate in human and mouse cells. Parasit Vectors, 8, 2015, 422.
83. [83] Soares, A.M.S., Carvalho, L.P., Melo, E.J.T., Costa, H.P.S., Vasconcelos, I.M., A protein extract and a cysteine protease inhibitor enriched fraction from Jatropha curcas seed cake have in vitro anti-Toxoplasma gondii activity. Exp. Parasitol. 153 (2015), 111–117.
84. [84] Anand, N., Sehgal, R., Kanwar, R.K., Dubey, M.L., Vasishta, R.K., Kanwar, J.R., Oral administration of encapsulated bovine lactoferrin protein nanocapsules against intracellular parasite Toxoplasma gondii. Int. J. Nanomed. 10 (2015), 6355–6369.
85. [85] Köksal, Z.S., Yanik, K., Bilgin, K., Yilmaz, E.M., Hokelek, M., In vivo efficacy of drugs acting on Toxoplasma gondii combined with immunomodulators. Jap. J. Infect. Dis. 69 (2016), 113–117.
86. [86] Belal, U.S., Norose, K., Mohamed, R.M., Sekine, S., Nukaga, T., Ito, K., Abdellatif, M.Z., Abdelgelil, N.H., Yano, A., Quantitative assessment of the effects of sulfamethoxazole on Toxoplasma gondii loads in susceptible WT C57Bl/6 mice as an immunocompetent model. Parasitol. Int. 65 (2016), 1–4.
87. [87] Kropf, C., Debache, K., Rampa, C., Barna, F., Schorer, M., Stephens, C.E., Ismail, M.A., Boykin, D.W., Hemphill, A., The adaptive potential of a survival artist: characterization of the in vitro interactions of Toxoplasma gondii tachyzoites with di-cationic compounds in human fibroblast cell cultures. Parasitology 139 (2012), 208–220.
88. [88] Mady, R.F., El-Hadidy, W., Elachy, S., Effect of Nigella sativa oil on experimental toxoplasmosis. Parasitol. Res. 115 (2016), 379–390.